Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens.
about
First line vs delayed transplantation in myeloma: Certainties and controversiesMultiple myeloma: 2014 Update on diagnosis, risk-stratification, and managementManagement of the adverse effects of lenalidomide in multiple myeloma.Overcoming the response plateau in multiple myeloma: a novel bortezomib-based strategy for secondary induction and high-yield CD34+ stem cell mobilization.Phase 2 trial of intravenously administered plerixafor for stem cell mobilization in patients with multiple myeloma following lenalidomide-based initial therapy.Plerixafor for PBSC mobilisation in myeloma patients with advanced renal failure: safety and efficacy data in a series of 21 patients from Europe and the USA.Lenalidomide in multiple myeloma: current experimental and clinical data.Update on immunomodulatory drugs (IMiDs) in hematologic and solid malignancies.Immunomodulatory drugs in multiple myeloma.Safety and efficacy of upfront plerixafor + G-CSF versus placebo + G-CSF for mobilization of CD34(+) hematopoietic progenitor cells in patients ≥60 and <60 years of age with non-Hodgkin's lymphoma or multiple myeloma.Cyclophosphamide, thalidomide, and dexamethasone (CTD) as initial therapy for patients with multiple myeloma unsuitable for autologous transplantation.Early versus delayed autologous transplantation after immunomodulatory agents-based induction therapy in patients with newly diagnosed multiple myeloma.Cyclophosphamide, thalidomide, and dexamethasone as induction therapy for newly diagnosed multiple myeloma patients destined for autologous stem-cell transplantation: MRC Myeloma IX randomized trial results.International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation.Induction therapy and stem cell mobilization in patients with newly diagnosed multiple myeloma.Myeloma today: Disease definitions and treatment advances.Higher Stem Cell Dose Infusion after Intensive Chemotherapy Does Not Improve Symptom Burden in Older Patients with Multiple Myeloma and AmyloidosisPresentation of multiple myeloma mimicking bone metastasis from colon adenocarcinoma: A case report and literature reviewAprepitant for prevention of nausea and vomiting secondary to high-dose cyclophosphamide administered to patients undergoing autologous peripheral blood stem cells mobilization: a phase II trial.Multiple myeloma: 2012 update on diagnosis, risk-stratification, and management.Multiple Myeloma, Version 2.2016: Clinical Practice Guidelines in OncologyBendamustine, bortezomib and prednisone for the treatment of patients with newly diagnosed multiple myeloma: results of a prospective phase 2 Spanish/PETHEMA trial.Evaluating the effects of lenalidomide induction therapy on peripheral stem cells collection in patients undergoing autologous stem cell transplant for multiple myelomaIs it feasible to use granulocyte-colony stimulating factor alone to mobilize progenitor cells in multiple myeloma patients induced with a cyclophosphamide, thalidomide and dexamethasone regimen?Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelinesLenalidomide, cyclophosphamide and dexamethasone (CRd) for newly diagnosed multiple myeloma: results from a phase 2 trial.Multiple myeloma: 2016 update on diagnosis, risk-stratification, and management.Outcomes of autologous transplantation for multiple myeloma according to different induction regimensCurrent multiple myeloma treatment strategies with novel agents: a European perspectiveLenalidomide in multiple myeloma: current role and future directions.How best to use new therapies in multiple myeloma.A single center's experience using four different front line mobilization strategies in lymphoma patients planned to undergo autologous hematopoietic cell transplantation.High rate of stem cell mobilization failure after thalidomide and oral cyclophosphamide induction therapy for multiple myeloma.Thalidomide, lenalidomide and bortezomib in the management of newly diagnosed multiple myeloma.How to treat patients with relapsed/refractory multiple myeloma: evidence-based information and opinions.Bortezomib for previously untreated multiple myeloma.Bisphosphonates as antimyeloma drugs.Plerixafor as first- and second-line strategies for autologous stem cell mobilization in patients with non-Hodgkin's lymphoma or multiple myeloma.Evaluation of the pharmacokinetics, preclinical, and clinical efficacy of lenalidomide for the treatment of multiple myeloma.The evolving role of plerixafor in hematopoietic progenitor cell mobilization.
P2860
Q26745957-9214496F-26F7-4F46-8C58-7229952C3101Q26998884-778865B7-8AD1-4959-B53E-4F023F6D4692Q33394632-371B501E-5DA3-46CD-905D-C942CFF0F4B9Q33405532-0E57C76D-F214-4AC2-B1AF-CAE6A78A5DF2Q33411277-7DFCA872-0D80-4A04-9F3C-5972207627A6Q33831680-D2BC967A-872C-4FBC-9A0A-09373EB93371Q34074803-256C629B-87A8-4CB6-8B68-9C52F93F264BQ34253548-CFC190A1-09B6-4A9D-94CC-22368118FA8AQ34325722-BAB02FEC-528E-4DDF-A5C6-E7B78DC58A11Q34971081-A76B4B53-6F2A-46C5-9757-17E1B6223F06Q35153760-F5B7C143-72C2-4803-903E-46DED062DE93Q35685454-D089513B-234F-4ECF-90DF-528F2CAAB885Q35794472-7ABAF495-C0B1-4E71-8532-64A243BEE111Q35802414-2AEC798E-F4D0-46E0-95AC-6D1C6274B0CAQ36014687-6F957F83-2671-4E12-A185-E1A6F32CEF4DQ36470699-CE4E30F6-4C31-47E8-BFD8-63B9D9E3127FQ36473988-EAE5B670-62D0-4A7C-BD8E-2966B7E7B0CFQ36503079-FCF9EF2A-13EF-4921-8FA3-0DD6B11FD128Q36673972-F5D5E205-B277-4587-A510-4256E18B252DQ36777233-5EF3BAC7-1D01-4D09-9C39-4E2B5BA19FB0Q36963203-09AE1B30-A7CB-45A6-AE3E-B4D7BB22302CQ37216380-8F98D498-525E-441B-A2AC-0BFF0133E476Q37335216-6B6C1833-38D2-4272-B335-8C17981E1638Q37429248-8CB3F4DC-D2F3-4241-BD97-28E572C02412Q37454445-52723F99-DD7A-4F78-ABA5-1DA74ED97554Q37515416-5FB78BD9-1F04-40A8-91CF-491B2A2DC936Q37623809-8AFC437D-2CD3-43C0-B07C-1BC3A16AE53EQ37628609-1E2B9E41-6DC8-4FF9-B9FA-5E888C2EC238Q37677935-6A21DC5E-7B4D-40ED-9FF4-CE252B3B7FC5Q37704401-85B1B94B-0D62-43B8-AA2E-8C569562ECBBQ37723000-A15031EF-418F-461E-A65D-0D7E486E7992Q37738995-8638CD61-CCCA-4A72-ACDD-43021DEC236CQ37766453-34FFE42F-C18A-4861-A802-2D031013EC6BQ37842346-49708D6B-4C3C-452E-837E-63ADFB586955Q37862262-450F4456-5C0F-4FDA-BE46-A8ABC9032DD9Q37937699-4EEBA662-E7B6-4154-8510-A4D4B4FF9F2EQ37946695-40338E46-A489-4B3A-AB03-E7437827727AQ38023761-CF5D3AED-CB90-4206-A388-AA4436287CB0Q38031989-A302F367-150C-4C65-A58F-62263F32894FQ38077807-CB590C24-C3BF-45BB-B73F-52E32F87B3D8
P2860
Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 26 June 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Mobilization in myeloma revisi ...... ortezomib-containing regimens.
@en
Mobilization in myeloma revisi ...... ortezomib-containing regimens.
@nl
type
label
Mobilization in myeloma revisi ...... ortezomib-containing regimens.
@en
Mobilization in myeloma revisi ...... ortezomib-containing regimens.
@nl
prefLabel
Mobilization in myeloma revisi ...... ortezomib-containing regimens.
@en
Mobilization in myeloma revisi ...... ortezomib-containing regimens.
@nl
P2093
P50
P1433
P1476
Mobilization in myeloma revisi ...... ortezomib-containing regimens.
@en
P2093
Brian G M Durie
David Vesole
Edward A Stadtmauer
Jean L Harousseau
Jesus San Miguel
Joan Blade
Leif Bergsagel
Michele Cavo
Nikhil Munshi
Orhan Sezer
P304
P356
10.1182/BLOOD-2009-04-205013
P407
P50
P577
2009-06-26T00:00:00Z